secwatch.observer — SEC 8-K summary
======================================

Issuer:     TENAX THERAPEUTICS, INC. (TENX)
CIK:        0000034956
Form:       8-K
Filed at:   2023-07-19T23:59:59+00:00
Accession:  0001654954-23-009414
Event type: regulatory
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tenax Therapeutics receives U.S. patent for oral levosimendan (TNX-103) in PH-HFpEF, expiring 2040
--------------------------------------------------------------------------------

- USPTO granted Patent No. 11,701,355 for oral levosimendan (TNX-103) to treat PH-HFpEF, with exclusivity through December 2040.
- No FDA-approved treatments exist for PH-HFpEF, which affects over 1.6 million North Americans, projected to exceed 2 million by 2030.
- Phase 2 HELP study showed statistically significant improvement in 6-minute walk distance for levosimendan.
- Tenax intends to initiate a Phase 3 trial of TNX-103 in 2023, planning to demonstrate efficacy in this underserved patient population.
- Patent builds on existing IP for IV and subcutaneous levosimendan formulations for PH-HFpEF.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/34956/000165495423009414/0001654954-23-009414-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/34956/000165495423009414/tenx_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-23-009414

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer